Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Soleno Therapeutics (SLNO) Operating Expenses (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed Operating Expenses for 9 consecutive years, with $52.2 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses changed N/A to $52.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $181.0 million through Dec 2025, changed N/A year-over-year, with the annual reading at $181.0 million for FY2025, 3.56% down from the prior year.
  • Operating Expenses for Q4 2025 was $52.2 million at Soleno Therapeutics, up from $43.9 million in the prior quarter.
  • The five-year high for Operating Expenses was $52.2 million in Q4 2025, with the low at $39.2 million in Q2 2025.